このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Adial Pharmaceuticals 過去の業績

過去基準チェック /06

Adial Pharmaceuticals は平均年間 0.9% の収益成長を遂げていますが、Pharmaceuticals 業界では年間減少率となっています。0.4% です。

主要情報

0.9%

収益成長率

31.6%

EPS成長率

Pharmaceuticals 業界の成長	6.0%
収益成長率	n/a
株主資本利益率	-183.6%
ネット・マージン	n/a
前回の決算情報	31 Mar 2024

Recent updates

Adial Clinical Trial: A Fluff Or A Win?

Aug 22

Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01

Aug 16

Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst

Jun 21

Adial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidate

Jan 11

Adial Pharmaceuticals inks stock purchase agreement with Keystone Capital

Nov 25

収支内訳

Adial Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqCM:ADIL 収益、費用、利益 ( )USD Millions
日付	収益	G+A経費	研究開発費
31 Mar 24	-11	5	1
31 Dec 23	-7	6	1
30 Sep 23	-8	6	2
30 Jun 23	-9	7	2
31 Mar 23	-10	8	2
31 Dec 22	-11	9	2
30 Sep 22	-14	9	4
30 Jun 22	-16	9	5
31 Mar 22	-17	9	7
31 Dec 21	-19	9	8
30 Sep 21	-17	9	8
30 Jun 21	-16	8	8
31 Mar 21	-13	7	7
31 Dec 20	-11	5	6
30 Sep 20	-9	5	5
30 Jun 20	-8	4	4
31 Mar 20	-8	4	4
31 Dec 19	-9	4	4
30 Sep 19	-8	4	3
30 Jun 19	-14	4	2
31 Mar 19	-14	3	1
31 Dec 18	-12	2	0
30 Sep 18	-11	1	0
30 Jun 18	-3	1	0
31 Mar 18	-1	1	0
31 Dec 17	-1	1	0
30 Sep 17	-1	1	0
30 Jun 17	-1	0	0
31 Mar 17	0	0	0
31 Dec 16	0	0	0

質の高い収益: ADILは現在利益が出ていません。

利益率の向上: ADILは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: ADILは利益を出していないが、過去 5 年間で年間0.9%の割合で損失を削減してきた。

成長の加速: ADILの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: ADILは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 19.9% ) と比較することは困難です。

株主資本利益率

高いROE: ADILは現在利益が出ていないため、自己資本利益率 ( -183.59% ) はマイナスです。

Adial Pharmaceuticals 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Recent updates

Adial Pharmaceuticals, Inc. Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $4.28365 million.

Adial Pharmaceuticals, Inc Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Adial Pharmaceuticals, Inc. announced that it has received $0.2875 million in funding

Price target decreased by 19% to US$21.00

New major risk - Share price stability

Price target decreased by 17% to US$17.00

Adial Pharmaceuticals, Inc. Appoints Tony Goodman as Chief Operating Officer

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement

Adial Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

Adial Pharmaceuticals, Inc. announced delayed amended 10-Q filing

Adial Pharmaceuticals, Inc. announced that it has received $4.000001 million in funding

Adial Pharmaceuticals, Inc. announced that it expects to receive $4.000001 million in funding

Adial Pharmaceuticals Receives Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence

Adial Pharmaceuticals, Inc., Annual General Meeting, Nov 02, 2023

Adial Pharmaceuticals, Inc. Announces Board Changes

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Adial Pharmaceuticals, Inc. announced delayed 10-Q filing

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement and Reduce the Public Float

New major risk - Share price stability

Adial Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Regarding Compliance with Nasdaq Listing Rule 5550(b)(1)

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Adial Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Adial Pharmaceuticals, Inc., Annual General Meeting, Oct 13, 2022

Adial Pharmaceuticals, Inc. Announces Executive Changes

Adial Clinical Trial: A Fluff Or A Win?

Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01

Adial Pharmaceuticals, Inc. Announces Topline Results For Onward Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder

Adial Pharmaceuticals Announces Database Lock for the ONWARD(TM) Phase 3 Clinical Trial

Price target increased to US$10.67

Adial Pharmaceuticals Announces Completion of Last Patient, Last Visit in its ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder

Adial Pharmaceuticals Receives Notice of Allowance on U.S. Patent for the Treatment for Opioid Use Disorder Using AD04

Independent Director recently bought US$67k worth of stock

Adial Pharmaceuticals, Inc. announced that it has received $0.8 million in funding from Bespoke Growth Partners, Inc.

Chairman recently bought US$55k worth of stock

Adial Pharmaceuticals, Inc. Announces Positive Pre-Clinical Data for PNV2 as A Drug Candidate for Triple Negative Breast Cancer

Director William Stilley has joined 3rd company board

Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder

Adial Pharmaceuticals, Inc. Reaches Full Enrollment Target for ONWARD Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder

Adial Pharmaceuticals, Inc. announced that it has received $5.000004 million in funding from Bespoke Growth Partners, Inc., Keystone Capital Partners LLC

Adial Pharmaceuticals Provides Regulatory and Development Update

Adial Pharmaceuticals, Inc. Plans to Enter Genetic Testing Market Following Allowance of U.S. Patent for Genetic Diagnostic Test

Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst

Adial Pharmaceuticals, Inc. announced that it has received $2.100003 million in funding from Keystone Capital Partners LLC, Bespoke Growth Partners, Inc., Rountop Limited Partnership, LLP and another investor

Forecast breakeven pushed back to 2024

Adial Pharmaceuticals Achieves 50% Enrollment in landmark ONWARD™ Phase 3 Trial

Adial Pharmaceuticals, Inc. to File Fast Track Application for Ad04 with the FDA

New 90-day high: US$3.19

Adial Pharmaceuticals, Inc. (NasdaqCM:ADIL) completed the acquisition of Purnovate, LLC from the members of Purnovate.

New 90-day high: US$2.34

Adial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidate

Adial Pharmaceuticals, Inc. (NasdaqCM:ADIL) entered into an Equity Purchase Agreement to acquire Purnovate, LLC from the members of Purnovate.

Adial Pharmaceuticals, Inc. Announces Management and Board Changes, Effective December 14, 2020

Adial Pharmaceuticals, Inc. announced that it expects to receive funding from Keystone Capital Partners LLC

Adial Pharmaceuticals inks stock purchase agreement with Keystone Capital

Adial Pharmaceuticals, Inc. Announces That U.S. Food and Drug Administration Issues an Emergency Use Authorization for the Assure/Fastep® Covid-19 Igg/Igm Rapid Test Device

Adial Pharmaceuticals, Inc. Files for Expedited Review of AD04 with the FDA

Adial Pharmaceuticals, Inc. announced that it has received $0.5 million in funding from Bespoke Growth Partners, Inc.

New 90-day low: US$1.21

Adial Pharmaceuticals, Inc. and Iremedy Healthcare Companies, Inc. Partner to Sell Covid-19 Antibody Test Kits to U.S. Medical Providers and Commence Sales

New 90-day low - US$1.32

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06